Streetbeat News

Products Services

PMVP

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) announced it will present updated Phase 1 data from the ongoing Phase 1/2 PYNNACLE study of PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The data will be discussed by the company's Chief Medical Officer and other experts during the conference. PMV will also host a KOL webinar to review the data and provide a regulatory update.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 4:05 pm

SNE

Sony has announced a new, smaller model of its PlayStation 5 (PS5) console, set to release on November 10. The new model is 30% smaller and 18% lighter than the current model, with a 20% increase in storage capacity. The price of the new model will be higher due to increased material costs. Sony aims to sell 25 million PS5 consoles worldwide by March 2024. The company hopes the new model will boost sales, following a similar strategy used with the PS4.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 4:00 pm

PHIO

Phio Pharmaceuticals announced the poster presentation of two key preclinical studies of its INTASYL compound PH-894 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. This announcement led to a rise in the company's share prices.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 4:00 pm

VALN

Valneva SE (NASDAQ:VALN) will present on the mosquito-borne chikungunya disease at several leading scientific conferences during Q4 2023. The presentations will cover various aspects of the disease, including its global threat, economic burden, and potential vaccination strategies. The global market for vaccines against chikungunya is estimated to exceed $500 million annually by 2032.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 3:46 pm

BIRK

CROX

DECK

NKE

German shoemaker Birkenstock Holding Plc (NYSE:BIRK) is set to debut on the NYSE after pricing its IPO at $46 per share, targeting a valuation of approximately $8.6 billion. The company plans to use the proceeds to repay borrowings and for general corporate purposes. Birkenstock sold approximately 30 million units in 2022, generating revenue of 1.24 billion euros ($1.32 billion) and net profit of 187 million euros on gross margins of 60%. The company's financial performance is largely dependent on brand perception, with risks including negative consumer perception, supply chain problems, and increasing competition from companies like Nike Inc (NYSE:NKE), Crocs Inc (NASDAQ:CROX), and Deckers Outdoor Corp (NYSE:DECK).

Portfolio Pulse from Adam Eckert

October 11, 2023 | 3:44 pm

PFE

The FDA has found no misconduct by Care Access in Pfizer's Lyme vaccine trial. The research company Care Access has announced the completion of a for-cause FDA Good Clinical Practices inspection related to the company's activities on Pfizer's Valor trial.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 3:36 pm

EWG

NVO

The German Drug Regulator BfArM has announced that it will coordinate an investigation into falsified Ozempic found in Germany. Ozempic is a product of Novo Nordisk (NVO).

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 3:35 pm

MDBH

Invizyne Technologies, a company from MDB Capital Holdings (NASDAQ:MDBH), has received an additional $3.77 million grant from the Bioenergy Technologies Office within the U.S. Department of Energy. The grant will be used to demonstrate Invizyne's cell-free production process for making isobutanol from plants in an energy-efficient manner. The global sustainable aviation fuel market, which includes isobutanol, is expected to grow at a compound annual rate of 52.2% to reach $27.4 billion by 2032.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 3:16 pm

BAX

DVA

FMS

ISRG

Shares of dialysis providers and kidney care stocks are trading lower after Novo Nordisk stopped its semaglutide kidney outcomes trial early based on early signs of efficacy. Companies potentially affected include BAX, DVA, FMS, and ISRG.

Portfolio Pulse from Bill Haddad

October 11, 2023 | 3:03 pm

INCY

Incyte (NASDAQ:INCY) has announced new results from its Phase 3 TRuE-V program, demonstrating the efficacy of continued treatment with Opzelura cream in nonsegmental vitiligo patients. The data shows that patients who initially experienced limited or no facial or total body repigmentation at six months achieved improved repigmentation after continued treatment with Opzelura for up to two years. The treatment was well-tolerated with no serious treatment-related adverse events reported.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 2:32 pm